IGM Biosciences
IGMS
IGMS was delisted on the 13th of August, 2025.
62 hedge funds and large institutions have $742M invested in IGM Biosciences in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 9 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
133% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 9
60% more capital invested
Capital invested by funds: $463M → $742M (+$279M)
24% more funds holding
Funds holding: 50 → 62 (+12)
4.42% more ownership
Funds ownership: 50.59% → 55% (+4.4%)
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$21.2M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11.8M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$8.75M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$7.15M |
| 5 |
BlackRock
New York
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$5.72M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.35M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$3.82M |
| 4 |
EP
Eversept Partners
New York
|
-$2.4M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$1.97M |
IGMS Hedge Fund Activity: Q1 2020 in Review
62 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q1 2020, worth a combined $742M — up 60% from $463M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IGMS positions and 9 closed out — a net gain of 12 holders — while 16 added to existing stakes and 17 trimmed.
The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $21.2M. The largest seller was Artal Group, exiting entirely with an estimated $5.72M sold.
- 62 institutional investors held IGM Biosciences (IGMS) as of Q1 2020, up from 50 in Q4 2019.
- Funds reported $742M of IGM Biosciences stock for Q1 2020, up 60% quarter-over-quarter.
- 21 funds opened new IGM Biosciences positions in Q1 2020 and 9 closed out, a net change of +12 holders.
- The largest IGM Biosciences buyer in Q1 2020 was Alkeon Capital Management, an estimated $21.2M added.
- The largest IGM Biosciences seller in Q1 2020 was Artal Group, an estimated $5.72M sold.
Based on aggregated 13F filings for Q1 2020.